Cang Zhu
Atractylodes lancea (Thunb.) DC.
Also known as: Atractylodes rhizome(English) 苍术(Chinese)
Sōjutsu蒼朮 ソウジュツ Changchul蒼朮 창출 Thương truật(source species Atractylodes lancea) Ts'ang Chu
Updated October 23, 2026 · Not yet clinically reviewed
Safety at a glance
5 recorded drug interactions
Contraindications or side effects are listed
No toxicity grade is recorded. Most herbs in the catalogue carry none.
Traditional Chinese Medicine
- Category
- transforming dampness
- Temperature
- Warm
- Taste
- Pungent,Bitter
- Channels
- Spleen,Stomach,Liver
Functions
Dries Dampness and strengthens the Spleen; Dispels Wind-Dampness; Releases the Exterior and Disperses Wind-Cold; Brightens the Eyes; Dispels Turbidity and Filth
Traditional uses
Cang Zhu (black atractylodes rhizome) is a warm, pungent-bitter herb with an intense Damp-drying and Spleen-strengthening action. It is the primary herb for treating Dampness obstructing the Middle Burner — conditions presenting with bloating, fatigue, heavy limbs, poor appetite, loose stools, and a thick, greasy tongue coating. It also expels Wind-Cold-Damp from the channels for joint pain and bodily heaviness from external dampness invasion. Burned as a fumigant, it was historically used to purify spaces during epidemic illness.
Western herbalism
Properties: carminative, diaphoretic, tonic
Pharmacological effects
- Fumigant disinfectant: Incense of Cang Zhu with Ai Ye was lethal to viruses (mumps, influenza), mycoplasma, bacteria and fungi; the decoction itself had no antimicrobial activity.
- Blood sugar: Decoction raised blood sugar in normal rabbits but lowered it in alloxan-diabetic rabbits; atractyloside (from A. gummifera) was hypoglycemic in several species.
- Other: Essential oil sedative in frogs, respiratory paralysis at high doses (β-eudesmol, hinesol); oil constituents inhibited esophageal carcinoma cells in vitro; atractylon inhibited TPA-induced ear inflammation and tumor promotion in mice.
Source: Zhu YP. Chinese Materia Medica: Chemistry, Pharmacology and Applications. Harwood Academic, 1998, p. 301.
Formulas using this herb
54 of 54 formulas
- Ba Xian Xiao Yao San · 10.00000g
- Bai Hu Jia Cang Zhu Tang 白虎加苍术汤 · 9.00000g
- Bu Huan Jin Zheng Qi San 不换金正气散 · chief
- Bu Pi Wei Xie Yin Huo Sheng Yang Tang 补脾胃泻阴火升阳汤 · 30.00000g
- Cang Fu Dao Tan Wan · 10.00000g
- Chai Ping Tang 柴平汤 · 6.00000g
- Chu Shi Juan Tong Tang · 6.00000g
- Chu Shi Wei Ling Tang 除湿胃苓汤 · 9.00000g
- Chun Yang Zheng Qi Wan · 30.00000g
- Da Qiang Huo Tang 大羌活汤
- Dan Xi Zhi Shi Tan Fang · 10.00000g
- Dang Gui Nian Tong Tang 当归拈痛汤 · 6.00000g · assistant
- Er Miao San 二妙散 · 15.00000g · deputy
- Er Zhu Tang 二术汤 · 4.50000g
- Fa Mu Wan 伐木丸 · 600.00000g
- Fen Xiao Tang 分消汤 · 3.00000g
- Gou Chong Wan · 20.00000g
- Huan Yin Jiu Ku Tang · 2.10000g
- Jia Wei Er Miao Wan 加味二妙丸 · 15.00000g
- Jia Wei Ping Wei San 加味平胃散
- Jin Huang San 金黄散 / 金黄膏 · 1000.00000g
- Jiu Wei Qiang Huo Tang 九味羌活汤 · 5.00000g · deputy
- Kai Yu Er Chen Tang · 9.00000g
- Li Shi Ban Xia Bai Zhu Tian Ma Tang · 6.00000g
- Liu Shen Tong Jie San 六神通解散 · 2.40000g
- Mu Xiang Shun Qi San · 6.00000g
- Nian Tong Tang 拈痛汤 · 9.00000g
- Ping Wei San 平胃散 · 12.00000g · chief
- Qing Re Zhi Dai Tang · 9.00000g
- Qing Shi Hua Tan Tang 清湿化痰汤 · 4.00000g
- San Miao Wan 三妙丸 · 18.00000g
- Sang Zhi Shi Gao Zhi Mu Tang 桑枝石膏知母汤
- Shan Zha Tang 山楂汤
- Shang Zhong Xia Tong Yong Tong Feng Wan 上中下通用痛风丸 · 21.00000g
- Sheng Ma Tang · 30.00000g
- Sheng Yang Chu Shi Tang · 3.00000g
- Shu Feng Huo Xue Tang 疏风活血汤 · 3.00000g
- Shu Jin Li An San 舒筋立安散
- Shu Jing Huo Xue Tang 疏经活血汤 · 3.00000g
- Si Miao Wan 四妙丸 · 12.00000g
- Tan Yin Wan 痰饮丸 · 90.00000g
- Tiao Zhong Yi Qi Tang 调中益气汤 · 1.50000g
- Tong Feng Wan 痛风丸
- Tong Qiao Tang · 3.00000g
- Wan Dai Tang 完带汤 · 9.00000g · deputy
- Wu Ji San 五积散
- Wu Jia Jian Zheng Qi San 五加减正气散 · 6.00000g
- Xiang Sha Ping Wei San 香砂平胃散 · 6.00000g
- Xiang Sha Yang Wei Tang 香砂养胃汤 · 2.40000g
- Xiao Feng San 消风散 · 3.00000g · deputy
- Xiao Ke Fang 消渴方
- Yi Yi Ren Tang 薏苡仁汤 · 3.00000g
- Yue Ju Wan 越鞠丸 · 6.00000g · chief
- Zha Qu Ping Wei San 楂曲平胃散 · 9.00000g
Botanical
Atractylodes lancea (Thunb.) DC. (Asteraceae) is a perennial herb 30-100 cm tall native to East Asia, with erect simple or sparingly branched stems, sessile leathery lanceolate to elliptic leaves with spiny-toothed margins (the lower often three-lobed), and terminal solitary thistle-like capitula of tubular white to purplish florets surrounded by pinnatifid spiny bracts. The knotty cylindrical to irregular rhizome, 3-10 cm long, exudes aromatic oil and shows red-brown oil glands ('zhusha dian', cinnabar spots) on the cut surface that turn into white needle-like crystals on standing. Rhizomes are dug in autumn or spring, sun-dried, and traditionally bran-fried. In TCM, Cang Zhu is acrid and bitter in flavor and warm in nature, entering the Spleen, Stomach, and Liver channels; it strongly dries dampness, strengthens the Spleen, and dispels wind-cold-damp.
- Family
- Asteraceae
- Pharmaceutical name
- Rhizoma Atractylodis
- Parts used
- rhizome
- Plant type
- herb
- Native region
- Hebei, Heilongjiang, Henan, Hubei, Jiangsu, Jilin, Liaoning, Inner Mongolia, Shanxi
Constituents
Atractylodin
Polyacetylene (polyyne) · Sole quantitative assay marker for Atractylodis Rhizoma in the Chinese Pharmacopoeia, which requires not less than 0.30% of the dried rhizome
The pharmacopoeial marker of the drug and the compound tracked in human pharmacokinetic work: after a single 1,000 mg dose of standardised Atractylodes lancea extract in healthy volunteers it is absorbed rapidly but reaches only low plasma concentrations (Cmax roughly 7-153 ng/mL) and is cleared within about 4 hours, with no accumulation over 21 days of dosing. In rodents it activates AMPK and reduces hepatic steatosis, and it is cytotoxic to cholangiocarcinoma cell lines in vitro.
beta-Eudesmol
Eudesmane sesquiterpene alcohol · Dominant volatile constituent of the Hubei chemotype of A. lancea; a minor component of the geo-authentic Maoshan chemotype
Accelerates gastric emptying and small-intestinal transit in mice, which is the experimental correlate of the drug's traditional use for epigastric fullness. It is metabolised in human liver microsomes chiefly by CYP2C19 with a secondary contribution from CYP3A4, and in isolated mouse diaphragm it potentiated depolarising neuromuscular blockade.
Hinesol
Spirovetivane sesquiterpene alcohol · Paired with beta-eudesmol as the chemical signature of the Hubei chemotype; the beta-eudesmol/hinesol ratio is largely genetically determined and is used to assign chemotype
One of the two sesquiterpene alcohols used to type A. lancea material by geographic origin. It contributes to the anti-ulcer and gastric acid-suppressing activity attributed to the volatile oil in animal models; human data specific to hinesol are lacking.
Atractylon
Eudesmane-type furanosesquiterpene · Together with atractylodin characterises the geo-authentic Maoshan (Mao Cang Zhu) chemotype; scarce in the Hubei chemotype
A chemically unstable furanosesquiterpene that degrades on storage and processing, which is part of why traditional processing and storage conditions alter the drug's profile. It carries anti-inflammatory and antitumour activity in cell-based assays.
Atractylodes lancea rhizome polysaccharide
Polysaccharide · Not standardised in the Chinese Pharmacopoeia; content varies with extraction method
The water-soluble, non-volatile fraction of the rhizome. In cyclophosphamide-immunosuppressed mice it restored immune parameters and reduced intestinal mucosal injury, an activity distinct from the volatile oil that dominates the drug's traditional reputation.
Drug interactions
CYP2C19 substrates (e.g. clopidogrel, omeprazole, diazepam, voriconazole)
Moderate · Potential altered exposure to the co-administered drug; clinical magnitude not established in humans · Evidence level: Possible
Reaction phenotyping in human liver microsomes and recombinant enzymes showed that beta-eudesmol, a major volatile constituent of A. lancea rhizome, is metabolised predominantly by CYP2C19 with a smaller contribution from CYP3A4 (Muhamad and Na-Bangchang 2023, in vitro). A shared metabolic route raises the possibility of competition at the enzyme, but no human interaction study has been performed and the systemic exposure achieved by the marker compound atractylodin after a 1,000 mg standardised-extract dose is low.
Clinical note: No dose change is indicated for decoctions at customary doses. If a patient is taking a narrow-therapeutic-index CYP2C19 substrate and is using concentrated or extract-based A. lancea products, monitor for altered drug effect rather than assume none.
CYP3A4 substrates (e.g. tacrolimus, ciclosporin, midazolam, statins)
Theoretical · Uncertain; no human data · Evidence level: Theoretical
The same in vitro reaction-phenotyping study identified CYP3A4 as a secondary route for beta-eudesmol metabolism. No induction or inhibition study of A. lancea against CYP3A4 probe substrates in humans has been published, so this is an inference from a shared pathway rather than a demonstrated interaction.
Clinical note: Flag rather than avoid. For transplant patients or others on narrow-therapeutic-index CYP3A4 substrates, prefer to keep herbal regimens stable and monitor drug levels through any change.
Depolarising neuromuscular blocking agents (succinylcholine)
Theoretical · Potential prolongation of neuromuscular blockade · Evidence level: Theoretical
beta-Eudesmol isolated from A. lancea potentiated depolarising neuromuscular blockade in isolated diaphragm muscle from normal and diabetic mice (Muroi et al. 1989, ex vivo). The concentrations used are far above anything plausibly reached from an oral decoction, and no clinical case has been reported.
Clinical note: Not a reason to withhold the herb, but include Cang Zhu in the pre-anaesthetic herbal history; the conventional advice to stop herbal medicines about a week before elective surgery applies.
Bai Zhu (Atractylodes macrocephala rhizome) substituted for Cang Zhu
Moderate · Wrong drug dispensed; different clinical action · Evidence level: Established
Cang Zhu (sojutsu) and Bai Zhu (byakujutsu, A. macrocephala) are distinct drugs from the same genus that are routinely confused in trade and in translation, and the older bencao literature did not separate them at all. Direct in vitro comparison of the two crude drugs found different anti-inflammatory and immunostimulative profiles (Shimato et al. 2017), and they differ chemically: Cang Zhu is defined by atractylodin, beta-eudesmol, hinesol and atractylon, while Bai Zhu is defined by atractylenolides. The Chinese Pharmacopoeia accepts A. lancea and A. chinensis (DC.) Koidz. as Cang Zhu; A. macrocephala is a separate monograph.
Clinical note: Confirm the botanical source on the certificate of analysis. Cang Zhu is the drying, dampness-transforming drug; Bai Zhu is the tonifying one, and substituting it changes the prescription's intent. Chloroplast trnK sequencing and HPLC marker profiles both distinguish the two reliably.
Antidiabetic agents (insulin, sulfonylureas, metformin)
Theoretical · Possible additive glucose lowering · Evidence level: Theoretical
A. lancea extract and atractylodin activate AMPK and improve hepatic lipid and glucose handling in rodent models of metabolic dysfunction-associated steatotic liver disease (Song et al. 2024, animal). No human glycaemic endpoint has been measured; the phase I trial in healthy volunteers reported no clinically significant laboratory changes.
Clinical note: No action required at customary doses. If a diabetic patient adds a concentrated extract, ask them to keep their usual glucose monitoring routine for the first few weeks.
Dosage
| Form | Amount | Frequency | Notes |
|---|---|---|---|
| decoction | 3–9 g | Daily | 中国药典 2020 【用法与用量】3~9g。 【性味与归经】辛、苦,温。归脾、胃、肝经。 — Chinese Pharmacopoeia 2020, quoted verbatim; route and cautions preserved. Replaces a cleared category-filler value. |
Dui yao: classical pairings
Cang Zhu + Bai Zhu白术
One dries and disperses dampness while the other tonifies the spleen, together both removing dampness and preventing its return.
Spleen deficiency with pronounced dampness.
Named pairing — Lü Jingshan, Shi Jinmo Dui Yao
Cang Zhu + Hou Po厚朴
Dries dampness and moves qi together, relieving the fullness and distention of dampness encumbering the spleen and stomach.
Epigastric and abdominal distention, no appetite, thick greasy tongue coating.
Core pair of a classical formula — Ping Wei San, Taiping Huimin Hejiju Fang
Cang Zhu + Huang Bai黄柏
Together they clear heat and dry damp in the lower burner, treating damp-heat descending to the legs.
Classic indication: hot, swollen, painful legs and knees, or damp-heat leukorrhea.
Core pair of a classical formula — Er Miao San, Dan Xi Xin Fa (Zhu Danxi)
Cang Zhu + Xuan Shen玄参
The moistening, yin-nourishing herb restrains the drying herb while the drying herb strengthens the spleen, a balanced pair Shi Jinmo used for wasting-thirst.
Named pairing — Lü Jingshan, Shi Jinmo Dui Yao
Evidence
Study design on record, not certainty of outcome.
- Randomized controlled trial
- 3
- In vitro / animal
- 4
Phase I clinical trial to evaluate the safety and pharmacokinetics of capsule formulation of the standardized extract of Atractylodes lancea
Na-Bangchang K; Kulma I; Plengsuriyakarn T; Tharavanij T; Kotawng K; Chemung A; Muhamad N; Karbwang J · Journal of Traditional and Complementary Medicine · 2021 · RCT
Randomized controlled trial · Not yet verified
Forty-eight healthy Thai volunteers received a single 1,000 mg oral dose, or 1,000 mg daily for 21 days, of a standardised ethanolic extract of A. lancea rhizome (about 48 mg atractylodin per dose) or placebo. The extract was well tolerated with no clinically significant adverse events or laboratory abnormalities. Atractylodin was absorbed rapidly but with low systemic exposure and short residence time, and repeated dosing produced no accumulation and no dose dependency, supporting 1,000 mg/day as a starting dose for cholangiocarcinoma trials.
A randomized placebo-controlled phase I clinical trial to evaluate the immunomodulatory activities of Atractylodes lancea (Thunb) DC. in healthy Thai subjects
Kulma I; Panrit L; Plengsuriyakarn T; Chaijaroenkul W; Warathumpitak S; Na-Bangchang K · BMC Complementary Medicine and Therapies · 2021 · RCT
Randomized controlled trial · Verified
A randomised, double-blind, placebo-controlled phase I trial in 48 healthy Thai subjects given a single or 21-day repeated 1,000 mg oral dose of standardised A. lancea extract. Single dosing significantly increased NK, CD4+ and CD8+ lymphocyte counts and lowered IFN-gamma and IL-10; repeated dosing significantly suppressed IL-17A and again raised CD4+ and CD8+ cells. In parallel in vitro work the extract, beta-eudesmol and atractylodin inhibited TNF-alpha and IL-6 expression in stimulated PBMCs. The endpoints are immunological markers, not clinical outcomes.
Exploratory Phase II Study of Atractylodes lancea (Thunb.) DC. in Advanced-Stage Intrahepatic Cholangiocarcinoma
Karbwang J; Tongsiri N; Plengsuriyakarn T; Sae-Heng T; Kongjam P; Kulma I; Worrabannakorn S; Na-Bangchang K · World Journal of Traditional Chinese Medicine · 2025 · RCT
Randomized controlled trial · Not yet verified
Forty-eight patients with advanced intrahepatic cholangiocarcinoma were randomised to 1,000 mg/day of the A. lancea capsule plus palliative care, an escalating 1,000-2,000 mg/day regimen plus palliative care, or palliative care alone, for three months with four months of follow-up. Both regimens were well tolerated; the higher-dose arm showed improved clinical response and quality-of-life scores, with reported gains in overall survival rate, disease control rate and progression-free survival versus supportive care alone. It is an exploratory study in 48 patients and is not a definitive efficacy trial.
The roles of CYP2C19 and CYP3A4 in the in vitro metabolism of beta-eudesmol in human liver: Reaction phenotyping and enzyme kinetics
Muhamad N; Na-Bangchang K · Pharmacology Research & Perspectives · 2023 · in vitro
In vitro / animal · Not yet verified
Human liver microsome and recombinant-enzyme phenotyping identified CYP2C19 as the principal enzyme metabolising beta-eudesmol, with CYP3A4 contributing secondarily. This is the main published basis for predicting pharmacokinetic drug interactions with Cang Zhu preparations; it is an in vitro study and has not been confirmed in humans.
Effects of an Atractylodes lancea rhizome extract and a volatile component beta-eudesmol on gastrointestinal motility in mice
Kimura Y; Sumiyoshi M · Journal of Ethnopharmacology · 2012 · animal
In vitro / animal · Verified
Oral A. lancea rhizome extract and isolated beta-eudesmol accelerated gastric emptying and small-intestinal transit in mice, and countered delayed transit induced by pharmacological blockade. This gives a mechanistic correlate for the traditional use of the rhizome in epigastric distension and poor appetite; it is a rodent study, not a clinical one.
Comparison of byakujutsu (Atractylodes rhizome) and sojutsu (Atractylodes lancea rhizome) on anti-inflammatory and immunostimulative effects in vitro
Shimato Y; Ota M; Asai K; Atsumi T; Tabuchi Y; Makino T · Journal of Natural Medicines · 2017 · in vitro
In vitro / animal · Verified
A head-to-head comparison of the two Atractylodes crude drugs that are routinely conflated. Sojutsu (A. lancea rhizome, Cang Zhu) and byakujutsu (Bai Zhu) produced different anti-inflammatory and immunostimulative profiles in cell-based assays, supporting the position that they are not interchangeable despite the shared genus.
Atractylodes Lancea and Its Constituent, Atractylodin, Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease via AMPK Activation
Song GY; Kim SM; Back S; Yang SB; Yang YM · Biomolecules & Therapeutics · 2024 · animal
In vitro / animal · Not yet verified
A. lancea extract and purified atractylodin reduced hepatic steatosis in a rodent model of metabolic dysfunction-associated steatotic liver disease, with AMPK activation identified as the mechanism. Preclinical only; no human metabolic endpoint has been tested.
Safety
Contraindications
Its use is prohibited in patients with yin deficiency and internal heat, and profuse sweating due to qi deficiency.
Source: Xi S, Gong Y. Essentials of Chinese Materia Medica and Medical Formulas. Academic Press/Elsevier, 2017, pp. 131–133.
Side effects
- No abnormalities in mice and rats fumigated 0.5 to 2 h with Cang Zhu/Ai Ye incense
- None of more than 4000 people exposed to the incense for 30 nights reported side effects
Source: Zhu YP. Chinese Materia Medica: Chemistry, Pharmacology and Applications. Harwood Academic, 1998, p. 301.
Cultural and historical
Shen Nong Ben Cao Jing (Divine Farmer's Classic of Materia Medica) · Han dynasty, compiled c. 200 CE
Ben Cao Jing Ji Zhu (Collected Commentaries on the Classic of Materia Medica), Tao Hongjing · Southern dynasties, c. 500 CE
Ben Cao Gang Mu (Compendium of Materia Medica), Li Shizhen · Ming dynasty, 1596
Pharmacopoeia of the People's Republic of China, Atractylodis Rhizoma (Cang Zhu) monograph · Modern standard, 2020 edition
Yin Shan Zheng Yao (Principles of Correct Diet), Hu Sihui · Yuan dynasty, 1330
References
- Zhang WJ; Zhao ZY; Chang LK; Cao Y; Wang S; Kang CZ; Wang HY; Zhou L; Huang LQ; Guo LP. Atractylodis Rhizoma: A review of its traditional uses, phytochemistry, pharmacology, toxicology and quality control. Journal of Ethnopharmacology. 2021 doi:10.1016/j.jep.2020.113415
- Sun J; Qiao J; Tang J; Cheng N; Gao M; Yang J; Kou B. Herbal Textual Research, Phytochemistry, Pharmacology and Toxicity of Atractylodis Rhizoma: A Comprehensive Review. Molecules. 2026 doi:10.3390/molecules31061015
- Xie J; Peng F; Yu L; Peng C. Pharmacological effects of medicinal components of Atractylodes lancea (Thunb.) DC.. Chinese Medicine. 2018 doi:10.1186/s13020-018-0216-7
- Saeheng T; Karbwang J; Na-Bangchang K. Population-pharmacokinetic/pharmacodynamic model of atractylodes lancea (Thunb.) DC. administration in patients with advanced-stage intrahepatic cholangiocarcinoma: a dosage prediction. BMC Complementary Medicine and Therapies. 2024 doi:10.1186/s12906-024-04618-8
- Mizukami H; Okabe Y; Kohda H; Hiraoka N. Identification of the Crude Drug Atractylodes Rhizome (Byaku-jutsu) and Atractylodes Lancea Rhizome (So-jutsu) Using Chloroplast TrnK Sequence as a Molecular Marker.. Biological and Pharmaceutical Bulletin. 2000 doi:10.1248/bpb.23.589